Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
The kit is developed for quantitative detection of natural and recombinant human IL-6 in serum, plasma and cell culture supernatants.
It is for research use only.
Assay Type | Sandwich-ELISA |
Analyte | IL-6 |
Format | 96-wells plate breakable into 12 x 8 wells strips |
Reactivity | Human |
Sensitivity | 2.0 pg/mL |
Assay Time | 1.75 hr |
Sample volume | 50 uL |
Range | 6.25 pg/mL-400 pg/mL |
Sample Type | Cell Culture Supernatants, Plasma, Serum. |
NIBSC Code | 89/548 |
Elevate your research experience with our Cytokine/Biomarker Detection Kits, where accuracy, reliability, and ease of use are converging to deliver exceptional results.
For each experiment, a standard curve needs to be set for each microplate, and the specific OD value may vary depending on different laboratories, testers, or equipment. The following example data is for reference only. The sample concentration was calculated based on the results of the standard curve. The minimum detectable concentration of IL-6 is less than 2.0 pg/mL.
Serum Sample – 240 samples from healthy volunteers were tested for the presence of human IL-6 concentration in the assay. 187 samples were detectable. No medical histories were available for the donors used in this study.
Cell Culture Supernatant – Human peripheral blood mononuclear cells (PBMCs) were cultured and stimulated with target cells at E:T ratios of 1:10 and 1:5, and then detect the secretion of IL-6 under stimulation with different concentrations of Blinatumomab.
5 types of materials were tested to observe if there were matrix effect (interference). If the concentration of bilirubin (simulated jaundice) is less than 20 mg/dL, the concentration of triglyceride (simulated lipid blood) is less than 3.0 mg/mL, the concentration of hemoglobin (simulated hemolysis) is less than 2% v/v, testing results will not be affected.
High concentrations of human IL-6 serum samples were diluted with 1:2, 1:4, 1:8, 1:16, 1:32 and 1:64 ratios for gradient dilution to evaluate the linearity of the assay. In the serum samples, the average detection rate of IL-6 was 98.43%.
10 replicates of each of 3 samples containing different IL-6 concentrations were tested in one assay. Acceptable criteria: CV<10%.
3 samples containing different concentrations of IL-6 were tested in the independent assays. Acceptable criteria: CV<15%.
IL-6 was spiked into 3 human serum samples, and then analyzed. The average recovery of IL-6 for serum samples is 94.64%.
ID | Components | Size |
CRB001-C01 | Pre-coated Anti-IL-6 Antibody Microplate | 1 plate |
CRB001-C02 | Human IL-6 Standard | 20 μg×2 |
CRB001-C03 | Biotin-Anti-IL-6 Antibody Con. Solution | 100 μL |
CRB001-C04 | Biotin-Antibody Dilution Buffer | 8 mL |
CRB001-C05 | Streptavidin-HRP Con. Solution | 500 μL |
CRB001-C06 | Streptavidin-HRP Dilution Buffer | 15 mL |
CRB001-C07 | 20× Washing Buffer | 50 mL |
CRB001-C08 | 1× Dilution Buffer | 15 mL×2 |
CRB001-C09 | Substrate Solution | 12 mL |
CRB001-C10 | Stop Solution | 6 mL |
Price(USD) : $515.00
Price(USD) :
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Lenalidomide | CC-5013; IMiD-3; ENMD-0997; STAR-LLD; IMID-5013; CDC-5013; CDC-501 | Approved | Celgene Corp | Revimid (former Brand Name), 瑞复美, Revlimid, Leavdo, Zelvina | United States | Myelodysplastic Syndromes | Bristol Myers Squibb Srlcompany | 2005-12-27 | Lymphoma, T-Cell, Peripheral; Lymphoma, B-Cell, Marginal Zone; Solid tumours; Bone Marrow Neoplasms; Kidney Neoplasms; Leukemia, Myeloid; Leukemia; Intestinal Neoplasms; Craniopharyngioma; Optic Nerve Glioma; Leukemia, Promyelocytic, Acute; Ovarian Neoplasms; Medulloblastoma; Ependymoma; Immunoproliferative Small Intestinal Disease; Leukemia, Erythroblastic, Acute; Hematologic Diseases; Liver Neoplasms; Plaque, Amyloid; Anemia; Pain; Paraproteinemias; Polycythemia Vera; Anemia, Refractory, with Excess of Blasts; Rhabdoid Tumor; Leukemia, Hairy Cell; Lymphoma, Large B-Cell, Diffuse; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Leukemia-Lymphoma, Adult T-Cell; Plasmacytoma; Hodgkin Disease; Graft vs Host Disease; Glioblastoma; Neoplasms; Blood Protein Disorders; Nerve Degeneration; Anemia, Refractory; Hypothalamic Neoplasms; Leukemia, Myelomonocytic, Acute; Pancreatic Neoplasms; Lymphomatoid Granulomatosis; Smoldering Multiple Myeloma; Multiple Myeloma; Urinary Bladder Neoplasms; Central Nervou | Details |
Luminol sodium | MP-1032 | Approved | Selvim, Metrio | Psoriasis; Immune System Diseases | null | 1997-01-01 | Coronavirus Disease 2019 (COVID-19); Immune System Diseases; Psoriasis; Plaque psoriasis | Details | ||
Pomalidomide | CDC-394; CC-4047; IMiD-1; IMID-4047 | Approved | Celgene Corp | Pomalyst, Imnovid, Actimid, Pomalyst/Imnovid, 安跃 | United States | Multiple Myeloma | Bristol-Myers Squibb Company | 2013-02-08 | Lung Diseases, Interstitial; Neurofibromatosis 1; Atypical Squamous Cells of the Cervix; Sarcoma, Kaposi; Anemia, Sickle Cell; Lymphoma, Non-Hodgkin; Carcinoma, Small Cell; Glioma; Waldenstrom Macroglobulinemia; Primary Myelofibrosis; Prostatic Neoplasms; Thrombocytosis; Sarcoma; Central Nervous System Neoplasms; Pulmonary Fibrosis; Medulloblastoma; Multiple Myeloma; Pancreatic Neoplasms; Hodgkin Disease; Plasmacytoma; Myeloproliferative Disorders; Immunoglobulin Light-chain Amyloidosis; Graft vs Host Disease; Scleroderma, Systemic; Renal Insufficiency; Polycythemia Vera; Bone Marrow Neoplasms; Solid tumours; Optic Nerve Glioma | Details |
Siltuximab | cCLB-8; CNTO-328 | Approved | Johnson & Johnson | Sylvant | United States | Multicentric Castleman's Disease (MCD) | Eusa Pharma | 2014-04-23 | Immunoglobulin Light-chain Amyloidosis; Leukemia, Large Granular Lymphocytic; Thrombocytopenia; Lung Neoplasms; Lymphoma, Non-Hodgkin; Primary Myelofibrosis; Castleman Disease; Colorectal Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Neoplasms, Plasma Cell; Prostatic Neoplasms; Multicentric Castleman's Disease (MCD); Monoclonal Gammopathy of Undetermined Significance; Lung Diseases; Multiple Myeloma; Respiratory Distress Syndrome, Adult; Bone Marrow Neoplasms; Pancreatic Neoplasms; Myelodysplastic Syndromes; Psychotic Disorders; Respiratory Tract Diseases; Smoldering Multiple Myeloma; Polycythemia Vera; Carcinoma, Renal Cell; Pneumonia; Schizophrenia; Diabetes Mellitus, Type 1; Ovarian Neoplasms; Cytokine Release Syndrome; Head and Neck Neoplasms; Respiratory Tract Infections; Kidney Neoplasms | Details |
Andrographolide/Sodium Hydrogen Sulfite | Approved | Bacterial Infections | Details | |||||||
Thalidomide | NSC-66847; NSC-527179; K-17; FPF-300; FPF300 | Approved | Celgene Corp | Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled | Mainland China | Leprosy, Lepromatous; Multiple Myeloma | Changzhou Pharmaceutical Factory | 1982-01-01 | Xerostomia; Colorectal Neoplasms; Neuroectodermal Tumors, Primitive; Prostatitis; Primary Myelofibrosis; Osteosarcoma; Cholangitis, Sclerosing; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Adenocarcinoma, Clear Cell; Carcinoma, Adenosquamous; Epilepsy; Erythema Nodosum; Sarcoma; HIV Wasting Syndrome; Pancreatitis, Chronic; Sarcoma, Ewing; Arachnoiditis; Gastrointestinal Hemorrhage; Retinoblastoma; Prostatic Neoplasms; Endometriosis; Lung Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Vascular Malformations; Myelodysplastic-Myeloproliferative Diseases; Mycobacterium avium-intracellulare Infection; Amyotrophic Lateral Sclerosis; Carcinoma, Hepatocellular; Burning Mouth Syndrome; Stomatitis; Neoplasm Metastasis; Appendiceal Neoplasms; Tuberculosis; Lymphoma, Non-Hodgkin; Angiodysplasia; Pelvic Pain; Glioma; Waldenstrom Macroglobulinemia; Leprosy, Lepromatous; Endometrial Neoplasms; Uterine Neoplasms; Anemia, Sideroblastic; Ovarian Neoplasms; Gastric Antral Vascular Ectasia; Lupus Erythematosus, Discoid; Carc | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Ensereptide | PXL-01 | Phase 3 Clinical | Promore Pharma | Tissue Adhesions; Post-surgical adhesions; Cicatrix | Details |
Olokizumab | CDP-6038; Anti-IL6-UCB | Phase 3 Clinical | Ucb | Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Lung Diseases, Interstitial; Arthritis; Crohn Disease | Details |
Efprezimod alfa | CD24-Fc; HAS-CD24; CD24-Fc-IgG; MK-7110; MK7110 | Phase 3 Clinical | Oncoimmune Inc | HIV Infections; Hematopoietic stem cell transplantation (HSCT); Solid tumours; Leukemia; Graft vs Host Disease; Coronavirus Disease 2019 (COVID-19); Myelodysplastic Syndromes; Dyslipidemias; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute; Melanoma | Details |
Ziltivekimab | COR-001; NN6018 | Phase 3 Clinical | Astrazeneca Plc | Heart Failure; Atherosclerosis; Anemia; Myocardial Infarction; Cardiovascular Diseases; Renal Insufficiency, Chronic; Inflammation; Systemic Inflammatory Response Syndrome | Details |
Clazakizumab | BMS-645429; ALD518-003; ALD-518; CSL300; BMS-945429; CSL-300 | Phase 3 Clinical | Alder Biopharmaceuticals | Cardiovascular Diseases; Stomatitis; Carcinoma, Non-Small-Cell Lung; Crohn Disease; Diabetes Mellitus; Kidney Failure, Chronic; Cachexia; Asthma; Arthritis, Psoriatic; Plaque, Atherosclerotic; Rejection of organ transplantation; Graft vs Host Disease; Arthritis, Rheumatoid; Fatigue; Coronavirus Disease 2019 (COVID-19); Atherosclerosis; Myocardial Infarction | Details |
Tabirafusp tedromer | KSI-501ABC; KSI-501 | Phase 3 Clinical | Kodiak Sciences Inc | Retinal Diseases; Wet Macular Degeneration; Diabetic macular oedema; Uveitis | Details |
Bezisterim | HE-3286; NE-3107 | Phase 3 Clinical | Harbor Therapeutics, Biovie Inc | Diabetes Mellitus, Type 2; Brain Injuries, Traumatic; Insulin Resistance; Arthritis, Rheumatoid; Post-Acute COVID-19 Syndrome; Alzheimer Disease; Parkinson Disease; Colitis, Ulcerative | Details |
Vamikibart | RO-7200220; RG-6179; EBI-031 | Phase 3 Clinical | Sesen Bio Inc | Macular Edema; Diabetic macular oedema | Details |
Sodium Hypochlorite | Phase 3 Clinical | Cystic Fibrosis; Pulpitis; Infections; Pain; Pain, Postoperative; Fibrosis; Dental Pulp Necrosis | Details | ||
PF-04236921 | PF-04236921; TOUR006; TOUR-006; PF-4236921 | Phase 2 Clinical | Pfizer Inc | Arthritis, Rheumatoid; Graves Ophthalmopathy; Lupus Erythematosus, Systemic; Cardiovascular Diseases; Renal Insufficiency, Chronic; Crohn Disease | Details |
Sirukumab | BA-003; CNTO-136 | Phase 2 Clinical | Glaxosmithkline Plc, Johnson & Johnson Innovative Medicine | Depressive Disorder, Major; Giant Cell Arteritis; Arthritis, Rheumatoid; Lupus Erythematosus, Cutaneous; Coronavirus Disease 2019 (COVID-19); Lupus Nephritis; Polymyalgia Rheumatica; Lupus Erythematosus, Systemic; Asthma | Details |
KSI-101 | KSI-501P; KSI-101 | Phase 2 Clinical | Kodiak Sciences Inc | Macular Edema | Details |
Anti-interleukin-6 receptor monoclonal antibody (Biocad) | Phase 2 Clinical | BIOCAD JSC | Autoimmune Diseases | Details | |
Isomyosamine | MYMD-1 | Phase 2 Clinical | Mymd Pharmaceuticals Inc | Anxiety; Frailty; Hashimoto Disease; Depression; Coronavirus Disease 2019 (COVID-19); Arthritis, Rheumatoid; Healthy Aging; Inflammation; Sarcopenia | Details |
FB-704A | FB-704; FB-704A | Phase 2 Clinical | Fountain Biopharma Inc | Arthritis, Rheumatoid; Asthma | Details |
Gerilimzumab | GB-224; RYI-008; ARGX-109 | Phase 1 Clinical | Argenx Se | Arthritis, Rheumatoid | Details |
MEDI-5117 | WBP-216; MEDI-5117 | Phase 1 Clinical | Wuxi Apptec Co Ltd, Medimmune | Arthritis, Rheumatoid | Details |
Tocilizumab biosimilar (Mycenax Biotech) | Phase 1 Clinical | Mycenax Biotech Inc | Arthritis, Rheumatoid | Details | |
SCD-153 | SCD-153 | Phase 1 Clinical | Sun Pharma Advanced Research Company Ltd, Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Johns Hopkins University | Alopecia Areata | Details |
NEX-20A | NEX-20A | Phase 1 Clinical | Nanexa AB | Multiple Myeloma | Details |
Luxeptinib | CG026806; CG-806; CG’806; CG-026806 | Phase 1 Clinical | Crystalgenomics Inc | Hematologic Neoplasms; Myelodysplastic Syndromes; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Wogonin | Shandong Buchang Pharmaceuticals Co Ltd, Hefei Cosource Medicine Technology, Daewoong Pharmaceutical Co Ltd, China Pharmaceutical University | Details |
This web search service is supported by Google Inc.